• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background

    Transverse Myelitis Companies

    ID: MRFR/MED/5028-HCR
    90 Pages
    Rahul Gotadki
    October 2025

    Transverse Myelitis companies are at the forefront of addressing this rare neurological disorder. Through dedicated research, development, and distribution, these organizations provide innovative treatments, contributing to improved outcomes and quality of life for individuals affected by transverse myelitis.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Top Industry Leaders in the Transverse Myelitis Market

    Transverse Myelitis Market

     


    Latest Transverse Myelitis Companies Updates:


    Annexon Biosciences (NASDAQ: ANEX): Announced positive Phase 2b data for their cannabinoid CB2 receptor agonist, CB2A-129, in treating acute optic neuritis, a condition often associated with transverse myelitis.


    Viela Bio (Viela Bio): Initiated a Phase 2 clinical trial evaluating their anti-IL-17A antibody, inebilizumab, for treating neuromyelitis optica spectrum disorder (NMOSD), a condition sometimes overlapping with transverse myelitis.


    Rare Disease Foundation: Launched a new initiative to raise awareness and support research for transverse myelitis and other rare neurological disorders.


    List of Transverse Myelitis companies in the market:



    • Medtronic, Inc.

    • B. Braun Melsungen AG

    • Fresenius Kabi AG

    • Baxter International, Inc.

    • Amgen Inc.

    • Johnson & Johnson Consumer Inc.

    • Bayer AG

    • Pfizer, Inc.

    • Cerus Corporation